Updated:
Zhejiang ZoneBanner JiuZhou Group
Zhejiang ZoneBanner JiuZhou Group was established in 1989 in Taizhou, Zhejiang, by entrepreneur Hua Xuande. The group's wealth originates from the...
Zhejiang ZoneBanner JiuZhou Group
Zhejiang ZoneBanner JiuZhou Group was established in 1989 in Taizhou, Zhejiang, by entrepreneur Hua Xuande. The group's wealth originates from the pharmaceutical and chemical industries, anchored by Zhejiang Jiuzhou Pharmaceutical Co., Ltd., a publicly listed company where Hua Xuande's daughter, Hua Lirong, serves as Chairman. The group operates as a corporate investor rather than a traditional family office, with Hua Xuande retaining control as the founding chairman of the parent entity. The group's investment activity follows the contours of its industrial origins. It allocates capital across pharmaceuticals, fine chemicals, logistics, real estate, and new energy. The pharmaceutical arm accounts for the bulk of its visible economic footprint, serving both domestic Chinese markets and export channels into regulated Western jurisdictions. Real estate exposure is concentrated in Taizhou through ZoneBanner Real Estate Development, which holds a mixed-use portfolio. While the group does not publicly break out deployment figures, its capital for direct investments and expansion projects is understood to come from retained operating profits across its industrial subsidiaries. Hua Lirong represents the second generation of family involvement, chairing the pharmaceutical subsidiary and sitting on the board of the China Pharmaceutical Innovation and Research Development Association (PhIRDA). The group maintains a philanthropic vehicle called the Jiuzhou Pharma Care Fund, though the separation between charitable assets and commercial operations is not publicly detailed. The structure suggests an industrial holding company model with a narrow philanthropic perimeter — common among Chinese corporate families with listed operating subsidiaries. No discrete investment team or AUM figure is disclosed. What distinguishes ZoneBanner JiuZhou is its structure as an operating-first conglomerate rather than a ring-fenced family office. There is no evidence of third-party capital or a formal co-investment program. Investment decisions appear to flow through the same governance that runs the operating businesses, creating a tight overlap between corporate strategy and family capital allocation. This makes the group less a standalone allocator and more an extension of the Hua family's industrial patrimony.
General information
Firm type
Corporate Investor
Year founded
1989
Location
Region
Asia
Country
China
City
Taizhou
Corporate office
Taizhou, Zhejiang, China
Principals
Hua Xuande
Founder and Chairman
Hua Lirong
Chairman, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Sector focus
Frequently asked questions
Who controls investment decisions at Zhejiang ZoneBanner JiuZhou Group?
The group does not publish a distinct investment committee. Hua Xuande, the founder and chairman, is the central figure, with his daughter Hua Lirong chairing the key pharmaceutical subsidiary. The governance structure suggests investment and operational decisions are intertwined at the ownership level.
Is Zhejiang ZoneBanner JiuZhou Group a single family office?
No. It is structured as a corporate investor — an industrial holding company controlled by the Hua family. It does not solicit or manage outside capital for discretionary allocation, which distinguishes it from registered asset managers, but it is not a ring-fenced family office in the Western sense. The family's wealth remains embedded in its operating subsidiaries.
What is the relationship between the group and Zhejiang Jiuzhou Pharmaceutical?
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is the publicly listed operating subsidiary that generates the bulk of the group's pharmaceutical revenue. Hua Lirong, the founder's daughter, chairs this entity. The parent group holds a controlling stake and consolidates the pharmaceutical business into its broader portfolio, which also includes chemical manufacturing, real estate, and logistics assets.
Does the group invest in external funds or only direct operating businesses?
Publicly available information does not show a fund commitment program. The group appears to deploy capital exclusively into subsidiaries and direct operating businesses that it controls. No evidence of LP commitments to external private equity, venture capital, or hedge funds has been identified in the public record.
Where does the underlying wealth come from?
The Hua family's wealth originates from pharmaceutical and chemical manufacturing, launched in Taizhou, Zhejiang in 1989. The group grew by supplying active pharmaceutical ingredients and intermediates to domestic and international markets, later diversifying into logistics, real estate, and new energy. The wealth is predominantly held through the parent group and its listed pharmaceutical arm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: